Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Mianserin

Plain-language summaryIntrigue 47 / 100

Mianserin is the older European cousin of mirtazapine, developed at Organon in the 1960s and marketed across Europe and Asia from 1976 onward. It was never approved in the United States. Like mirtazapine it boosts norepinephrine and serotonin output by blocking the auto-brake on those neurons rather than blocking the reuptake pumps. The differences are subtle: mianserin has a wider spread of off-target receptor activity and a small but historically significant risk of bone marrow suppression, which is part of why mirtazapine ultimately replaced it in most markets. Mianserin remains useful as a research tool for understanding the alpha-2 adrenergic receptor mechanism. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Superseded tetracyclic antidepressant with limited modern research appeal beyond mirtazapine comparison work

Look, mianserin is the compound mirtazapine quietly replaced. Organon developed it in the 1960s, got it onto the European and Asian market in 1976, and then spent the next two decades iterating toward a safer, cleaner successor. That successor is mirtazapine. The story of mianserin is, in a meaningful sense, the story of what had to be fixed to get there.

The mechanism is genuinely interesting in outline: alpha-2 adrenergic auto- and heteroreceptor antagonism drives monoaminergic disinhibition in a way thats actually pharmacologically elegant compared to older tricyclics. You also get 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism in the mix. But every one of those receptor interactions is better characterized in mirtazapine, and mirtazapine does it without the agranulocytosis and aplastic anemia risk that haunted mianserin’s clinical career — estimated at roughly 1 in 1500 to 1 in 5000 cases, which is hard to ignore when a structurally similar compound with a cleaner safety profile exists.

The evidence base is real. Decades of European clinical use, multiple controlled trials, established PK (half-life 21-61 hours, CYP2D6 metabolism, active demethyl-mianserin metabolite). This isnt a compound with thin preclinical-only data. But the evidence is aging, the trials are mostly pre-2000, and virtually no active research programs are centering mianserin as a primary object of study. The literature is large because it was used, not because researchers are still reaching for it.

What bench value mianserin retains is narrow. It works as a reference compound in alpha-2 pharmacology comparisons and as a historical control when studying tetracyclic antidepressant mechanisms. If your research question specifically involves comparing first- versus second-generation tetracyclics, or quantifying the receptor-selectivity improvements that mirtazapine achieved, then mianserin is the natural comparator. Outside that framing, its hard to construct a reason to run an experiment with mianserin when mirtazapine exists and is more widely available.

We dont think this belongs on a frontier research shortlist. The novelty is low, the differentiation is negative relative to its own successor, and the research signal it carries is historical rather than prospective. Serious investigators working in adrenergic or tetracyclic antidepressant pharmacology probably already know where mianserin fits. For anyone else, the compound earns a file entry and not much more.

Novelty

18

Mechanism promise

28

In-category differentiation

18

Evidence quality

58

Translational signal

55

Research bench value

30

Rationale Mianserin’s core mechanism is well-understood and has been materially improved upon by mirtazapine, which retains the pharmacologically interesting alpha-2 antagonism while shedding the agranulocytosis liability; novelty and differentiation scores drag the overall down hard. Evidence quality and translational signal are real but historically bounded and largely irrelevant to active research programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tetracyclic alpha-2 adrenergic antagonist

A first-generation tetracyclic antidepressant; the structural and mechanistic precursor to mirtazapine.

Abstract

Mianserin (1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; CAS 24219-97-4; molecular formula C18H20N2; molecular weight 264.37) is a tetracyclic antidepressant developed at Organon in the 1960s and marketed in Europe and Asia from 1976 (never FDA approved for the US market). The compound is the structural and mechanistic precursor to mirtazapine, sharing the alpha-2 adrenergic auto/heteroreceptor antagonism that increases monoaminergic release. Mianserin additionally exhibits 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism but with a less favorable receptor selectivity profile than mirtazapine. Notable for a higher incidence of agranulocytosis and aplastic anemia than mirtazapine (estimated 1 in 1500 to 1 in 5000 cases) which contributed to its replacement in clinical practice. Plasma half-life is 21 to 61 hours; metabolism is via CYP2D6 with active demethyl-mianserin metabolite. Used as a reference tetracyclic and alpha-2 antagonist in mechanism studies; less common in clinical use today owing to mirtazapine availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-214Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sembragiline

Plain-language summaryIntrigue 40 / 100

Sembragiline is an investigational selective reversible MAO-B inhibitor from Roche and EVOTEC, originally developed as a possible Alzheimer disease treatment. The rationale was elegant: MAO-B is upregulated in the reactive astrocytes that surround amyloid plaques in Alzheimer brain tissue, and that upregulation contributes to oxidative damage. Selectively shutting it down with a reversible blocker should, in theory, reduce that damage without interfering with normal brain function. The Phase 2 MAyflOwer RoAD trial in mild-to-moderate Alzheimer disease failed to show clinical benefit, however, and development was halted. The compound retains research value as a mechanistic probe but has no clinical future. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

38/100

Failed Alzheimer phase 2 candidate with residual tool value as a clean reversible selective MAO-B probe

Look, sembragiline is a clean story about a drug that asked the right question and got the wrong answer. The mechanistic rationale was genuinely reasonable: MAO-B is upregulated in reactive astrocytes in Alzheimer brain tissue, it contributes to oxidative stress, and there’s a plausible chain from that to amyloid pathology. Roche and Evotec built a highly selective reversible inhibitor to probe this, with a selectivity ratio above 1000:1 over MAO-A. Thats pharmacologically elegant. The reversibility angle was the key idea: unlike selegiline or rasagiline, which ablate MAO-B activity for the life of the enzyme, sembragiline gives you tunable, titratable inhibition without committing to an irreversible mechanism.

Then the MAyflOwer RoAD trial happened. Phase 2, n=542, mild-to-moderate Alzheimer disease, 52 weeks. No significant slowing of cognitive decline. Development halted. The compound didn’t fail because of bad pharmacology; it failed because the hypothesis didn’t translate. MAO-B inhibition in Alzheimer’s turned out not to be a sufficient lever on disease progression, at least not at the population level or the dose ranges tested.

What’s left is a genuinely useful but narrow tool compound. Academic neuroscience groups use sembragiline specifically because of what it is: the reference reversible selective MAO-B inhibitor with the cleanest selectivity profile available. If you’re studying MAO-B’s contribution to neuroinflammatory signaling, dopamine metabolism in Parkinson’s-adjacent biology, or oxidative stress dynamics in reactive astrocytes, you need something that lets you toggle the enzyme without the complication of irreversibility. Safinamide is also reversible and approved, but it carries a sodium channel component that complicates clean mechanistic attribution. Sembragiline is cleaner for this purpose.

We think the bench value is real but specific. If your research program touches MAO-B biology directly, this is worth having and using. If it doesn’t, theres not much here. The failed phase 2 is decisive for the Alzheimer’s indication, and the compound has no obvious pivot to another indication with real human signal. Novelty is modest: MAO-B inhibition is a mature mechanistic class, and reversible selectivity within it is a refinement, not a new direction.

Honestly, what keeps this at 38 is arithmetic. The mechanism class is established, the clinical hypothesis was falsified, and the tool value is specific enough to matter only to a subset of neuroscience programs. Sembragiline ran a clean trial and learned something real. That’s exactly what research should do. It just doesn’t make the compound a priority target for most investigators, and the score should say so plainly.

Novelty

32

Mechanism promise

35

In-category differentiation

48

Evidence quality

44

Translational signal

22

Research bench value

55

Rationale Sembragiline’s mechanistic rationale was scientifically sound but the MAyflOwer RoAD trial (n=542, 52 weeks) produced a clear null result, decisively closing the AD indication. Its remaining value is as the reference reversible, highly selective MAO-B inhibitor (greater than 1000:1 over MAO-A) for academic studies of MAO-B’s contribution to neurodegeneration, but that utility is narrow enough that bench_value can’t rescue the overall from niche-probe territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective reversible MAO-B inhibitor (investigational)

A selective reversible MAO-B inhibitor investigated for Alzheimer disease; failed phase 2 efficacy.

Abstract

Sembragiline (EVT-302, RG1577; molecular formula C19H22FN3O; molecular weight 327.40) is a selective reversible MAO-B inhibitor developed at Roche and EVOTEC as a candidate for Alzheimer disease. The mechanistic rationale: MAO-B is upregulated in reactive astrocytes in Alzheimer brain tissue, contributing to oxidative stress and amyloid pathology; selective reversible inhibition might reduce this contribution without the irreversible enzyme abolition of selegiline or rasagiline. Phase 2 MAyflOwer RoAD trial in mild-to-moderate Alzheimer disease (n=542) failed to show significant slowing of cognitive decline at 52 weeks; development was halted. The compound retains research utility as a clean tool for selective reversible MAO-B inhibition (selectivity ratio greater than 1000:1 over MAO-A) and is used in academic studies of MAO-B’s role in neurodegeneration. Used as the reference reversible selective MAO-B inhibitor in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-231Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vigabatrin

Plain-language summaryIntrigue 69 / 100

Vigabatrin (Sabril) is a so-called suicide inhibitor of GABA transaminase, the enzyme that breaks down the brain’s main inhibitory neurotransmitter. The vinyl group on the molecule converts vigabatrin into a fake substrate that the enzyme attempts to process and is then permanently destroyed by; the only way the brain restores normal GABA breakdown is to manufacture new enzyme from scratch. The result is sustained and powerful elevation of brain GABA levels. It is uniquely effective in infantile spasms (a devastating early-childhood seizure disorder) and refractory complex partial seizures. The catch is severe and irreversible: roughly a third of patients develop permanent visual field constriction from retinal toxicity. That has restricted it to cases where no alternative works. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

53/100

The canonical irreversible GABA-T suicide inhibitor, clinically validated but mechanistically mature and toxicity-constrained

Vigabatrin has been in the clinic since 1989 in Europe, with US approval following in 2009. That timeline matters for how you read the score. This isnt a compound at the frontier of anything; it’s a compound that already did its frontier work decades ago and has been in routine use ever since.

The mechanism is genuinely clever, and worth understanding on its own terms. The vinyl group at the alpha-carbon turns vigabatrin into a substrate that GABA transaminase begins to process but can’t release. The result is irreversible covalent inactivation of the enzyme, with GABA degradation capacity only restored by de novo enzyme synthesis. That makes the pharmacodynamic window substantially longer than the plasma half-life of 5 to 13 hours would suggest. As a piece of chemical biology, suicide inhibition is elegant; as a research tool, the irreversibility is actually useful for experiments requiring sustained, stable GABA-T suppression without continuous re-dosing.

The clinical translational story is real and worth acknowledging directly. For infantile spasms, specifically West syndrome, the treatment options are limited and vigabatrin is one of them. The UKISS trial and the pivotal FDA registration studies, particularly for tuberous sclerosis-associated spasms, showed meaningful seizure suppression where many anticonvulsants fail. That’s a durable human signal, not a preclinical artifact.

The problem, and it’s not a minor one, is the retinal toxicity. Bilateral concentric visual field constriction in roughly 30 to 50 percent of long-term users. Irreversible. The FDA REMS program exists because of this, mandating baseline and periodic visual field testing. Current research thinking attributes the damage to GABA accumulation in retinal photoreceptors. For bench investigators, this means any animal model work with vigabatrin has to account for retinal off-target effects as a confound.

We think vigabatrin earns a library spot specifically as a reference probe. If your research program touches GABA metabolism, inhibitory circuit modulation, or mechanism-based enzyme inhibition as a chemical strategy, vigabatrin is the standard. No other approved compound does what it does to GABA-T. What it doesnt offer is novelty, a growing literature edge, or any real frontier signal. The mechanistic questions are settled, the clinical niche is narrow, and the toxicity profile constrains enthusiasm for new indication discovery. A serious bench scientist working on GABAergic biology needs this compound; a scientist looking for their next interesting target probably doesnt start here.

Novelty

22

Mechanism promise

42

In-category differentiation

60

Evidence quality

76

Translational signal

70

Research bench value

65

Rationale Vigabatrin earns solid evidence and translational scores given FDA approval, REMS-backed safety surveillance, and real infantile spasms efficacy, but novelty is low for a compound with 35-plus years of literature and a fully characterized mechanism; primary research value now sits in its role as the definitive irreversible GABA-T probe for GABAergic circuit and enzyme kinetics work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA transaminase inhibitor (irreversible)

An irreversible suicide inhibitor of GABA transaminase; uniquely effective in infantile spasms and refractory complex partial seizures, limited by retinal toxicity.

Abstract

Vigabatrin ((R/S)-4-aminohex-5-enoic acid; CAS 60643-86-9; molecular formula C6H11NO2; molecular weight 129.16) is a vinyl-GABA suicide inhibitor of GABA transaminase developed at Marion Merrell Dow and approved by the FDA in 2009 under the trade name Sabril (later than European registration in 1989). Mechanism: the vinyl group at the alpha-carbon converts vigabatrin into a substrate that the GABA transaminase enzyme begins to process but cannot release; the result is irreversible covalent enzyme inactivation, requiring de novo enzyme synthesis to recover GABA degradation capacity. The consequence is sustained elevation of brain GABA concentrations. Effective in infantile spasms (West syndrome) where conventional anticonvulsants often fail, and as adjunctive therapy in refractory complex partial seizures. The principal limitation is irreversible bilateral concentric visual field constriction in approximately 30 to 50 percent of long-term users, attributed to retinal photoreceptor damage; the FDA REMS program requires baseline and periodic visual field assessment. Plasma half-life is 5 to 13 hours, but the irreversible enzyme inhibition produces effective activity beyond the plasma window. Used as the canonical GABA transaminase suicide inhibitor.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-246Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Testolone (RAD-140)

Our opinion on this compoundEstablished, active research

50/100

Highest-potency SARM with a real clinical trajectory in breast cancer, but mechanism maturity limits ceiling

RAD-140 is probably the most potent SARM in the research toolkit, and that does matter for how you use it on the bench. With a Ki around 7 nM and intrinsic activity that in some preclinical models exceeds testosterone propionate at equivalent molar doses, it’s not a subtle tool. The selectivity profile – meaningful anabolic activity with reduced androgenic effects in prostate tissue compared to steroidal androgens – is what got Radius Health interested in the first place, and it’s still the core value proposition.

The breast cancer angle is where things get genuinely interesting. AR-positive metastatic breast cancer is a real clinical problem with limited options, and the phase 1 data in postmenopausal women did show dose-dependent AR pathway engagement. The program moved into phase 2, which puts RAD-140 in a much smaller club than most SARMs that never get near a clinic. Thats worth noting when you’re assessing the translational signal here.

So why a 50? Honestly, the SARM mechanism is the limiting factor. Tissue-selective AR agonism is well-understood at this point – the co-activator recruitment story, the differential downstream signaling in muscle versus prostate, the axis suppression trade-offs. None of that is new. And the SARM space has been actively researched for long enough that what once felt genuinely novel now feels like a crowded field. RAD-140 is the highest-potency member of an increasingly mature class.

The evidence situation is better than most SARMs but still limited by phase 2 standards. Phase 1 data really just establishes that the target is engaged and acute tolerability is acceptable. We dont yet have efficacy data that would move a serious investigator from “interesting” to “important.” Long-term safety is a genuine unknown, HPG suppression is a real concern at pharmacological doses, and hepatic enzyme elevation signals at supratherapeutic exposures add caution flags for extended study designs.

As a bench tool, RAD-140 is actually quite useful. If you’re studying AR selectivity, differential co-activator biology, or SARM-class pharmacokinetics – that approximately 60-hour half-life is unusually long for the class – it gives you a high-signal probe. The widespread recreational use, frustrating from a regulatory standpoint, has generated a substantial body of observational pharmacokinetic data that investigators sometimes find valuable for dose-ranging rationale in study design.

We think this sits firmly in established-active territory. The breast cancer indication keeps it clinically relevant and worth watching; the mechanism maturity and evidence ceiling keep it from scoring higher.

Novelty

44

Mechanism promise

48

In-category differentiation

55

Evidence quality

48

Translational signal

50

Research bench value

58

Rationale RAD-140 earns its place as the benchmark high-potency SARM with actual phase 1/2 clinical data in AR-positive breast cancer, but tissue-selective AR agonism is a well-understood mechanism in an increasingly crowded class, and evidence quality stops well short of replicated phase 3 data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective androgen receptor modulator (high-potency)

A potent non-steroidal SARM developed for muscle wasting and breast cancer; one of the highest-potency SARMs by binding affinity.

Abstract

Testolone (RAD-140; CAS 1182367-47-0; molecular formula C20H16ClN5O2; molecular weight 393.83) is a non-steroidal SARM developed by Radius Health for muscle wasting and (subsequently) AR-positive metastatic breast cancer. The compound is a high-potency AR ligand (Ki approximately 7 nM with high intrinsic activity) and a tissue-selective agonist; preclinical studies demonstrated anabolic activity in skeletal muscle exceeding that of testosterone propionate at equivalent molar doses, with reduced prostate effects. Phase 1 trials in postmenopausal women with metastatic breast cancer demonstrated dose-dependent AR pathway engagement; the program was advanced into phase 2. The compound is among the most widely used SARMs recreationally despite no regulatory approval. Plasma half-life is approximately 60 hours, supporting once-daily dosing. The principal safety concerns are HPG axis suppression and hepatic enzyme elevation at supratherapeutic doses; long-term safety data are absent.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-263Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
RU58841

Plain-language summaryIntrigue 55 / 100

RU58841 is a topical androgen receptor blocker developed by Roussel-Uclaf in the 1990s as a hair-loss treatment. The idea was elegant: rather than systemically lowering DHT (and risking sexual side effects), apply an AR blocker directly to the scalp where it competes with DHT at the hair follicle, with minimal absorption into the rest of the body. Phase 1 and 2 trials showed efficacy in slowing or reversing male-pattern baldness, but the compound was abandoned commercially (the reasons remain unclear and the compound was simply shelved). It is now used in DIY scalp solutions sourced as a research chemical, with minimal long-term safety data and no manufacturer accountability. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

A 1990s topical AR antagonist with real phase 2 data, now largely eclipsed by clascoterone

Look, RU58841 is a compound that almost made it. Roussel-Uclaf synthesized this hydantoin in the early 1990s with a genuinely smart idea behind it: get an AR antagonist into the scalp follicle without the systemic exposure that makes drugs like flutamide a liability. The structure binds the AR with enough affinity to compete with DHT locally, and if you keep it topical, you theoretically sidestep the sexual side effects that plagued oral antiandrogen use. Phase 1 and phase 2 trials were run, hair retention signals were real, and then the corporate machinery of a Sanofi merger ground the program to a halt. Not because it failed. Because priorities shifted.

That history matters for how we score it. We’ve got actual human data, which puts RU58841 ahead of a lot of compounds in this library that are still swimming in rodent studies. Phase 2 efficacy is real evidence. But the data is also thirty years old, never advanced to phase 3 confirmation, and hasnt been meaningfully replicated by independent groups in modern trial formats. What we have is a snapshot of mid-90s clinical pharmacology, not a living literature.

The bigger issue for differentiation is clascoterone. Cassiopea got Winlevi approved by the FDA in 2020, first as a topical AR antagonist for acne, and its been investigated for androgenetic alopecia since. That approval changes the landscape. RU58841 was the only reference topical AR antagonist for about two decades; now there’s a regulatory-approved alternative with a cleaner development history and ongoing Phase 2/3 AGA work. RU58841 doesn’t disappear from the toolbox, but it stops being the only option.

Where it still earns its keep is as a bench probe. If you’re studying follicular androgen biology, mapping AR occupancy in explant models, or trying to isolate DHT-mediated effects in scalp tissue, RU58841 is a well-characterized reference with published pharmacokinetics and selectivity data. Thats real utility for a narrow but serious research program. We dont dismiss that. But it’s probe value, not frontier value.

Honestly, the compound sits in a frustrating middle ground: too much evidence to call it speculative, not enough development to call it mature, and now partially overshadowed by a compound that finished what it started. A serious AGA researcher in 2025 would probably reach for clascoterone first and keep RU58841 as a backup reference tool. That’s the honest picture.

Novelty

20

Mechanism promise

35

In-category differentiation

45

Evidence quality

50

Translational signal

50

Research bench value

58

Rationale RU58841 scores low on novelty because it is a three-decade-old hydantoin developed at Roussel-Uclaf using straightforward single-receptor AR antagonism; its phase 2 human data lifts evidence and translational scores above most research peptides, but those gains are offset by commercial abandonment and the subsequent approval of clascoterone (Winlevi) as a topical AR antagonist, which erodes its differentiation. Bench value survives as a reference compound for follicular AR pharmacology, preventing a lower overall.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Topical androgen receptor antagonist

A topical non-steroidal AR antagonist developed for androgenetic alopecia; never advanced to commercial development but widely used as a research compound.

Abstract

RU58841 (PSK3841; CAS 154992-24-2; molecular formula C17H18F3N3O3; molecular weight 369.34) is a non-steroidal androgen receptor antagonist developed at Roussel-Uclaf (now Sanofi) in the 1990s as a topical treatment for androgenetic alopecia. The compound is structurally a hydantoin and binds the AR with sufficient affinity to compete with DHT in scalp tissue. Topical application allows local AR antagonism in hair follicles with minimal systemic absorption, theoretically avoiding the sexual side effects of systemic 5AR inhibitors. Phase 1 and 2 trials demonstrated efficacy in slowing or reversing scalp hair loss. Development was discontinued at Roussel-Uclaf (subsequent corporate merger and prioritization). The compound entered the research-grade and DIY hair loss community via the published patents and has remained in informal use without regulatory approval. Used as a reference topical AR antagonist in dermatologic and androgen pharmacology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-281Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cotadutide

Plain-language summaryIntrigue 65 / 100

Cotadutide is a dual GLP-1 and glucagon receptor agonist from AstraZeneca, investigated for type 2 diabetes, fatty liver disease, and obesity. It is a balanced co-agonist (about 5:1 GLP-1 to glucagon). The GLP-1 component does the usual incretin work: insulin release, glucagon suppression, appetite reduction. The glucagon component independently raises energy expenditure and lipolysis, theoretically adding fat-burning on top of appetite suppression. Phase 2 trials showed strong glycemic and weight effects. AstraZeneca de-prioritized it in 2023 in favor of other pipeline assets, leaving its commercial future unclear. The dual-agonist concept lives on in mazdutide and survodutide. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

63/100

Dual GLP-1/glucagon agonist with a genuine NASH thesis and real Phase 2 metabolic signal

Cotadutide sits in an interesting position in the incretin landscape. It’s not tirzepatide, it’s not retatrutide, and it was never meant to be. What it is: a carefully balanced dual GLP-1/glucagon agonist with a specific research thesis around hepatic fat clearance that pure GLP-1 drugs can’t match on mechanism.

The core design is a roughly 30 amino acid peptide with a C16 fatty acid extension, biased approximately 5:1 GLP-1:glucagon at receptor. The GLP-1 side handles what you’d expect: glucose-dependent insulin secretion, glucagon suppression, appetite attenuation. The glucagon component is where it gets interesting. Glucagon receptor activation in the liver directly drives fatty acid oxidation and lipolysis independent of the GLP-1 effects. Thats the NASH thesis: if you can drive hepatic fat clearance through a mechanism that pure GLP-1 agonism doesnt fully access, you get additive benefit at the liver. Phase 2 data (NCT03205761 and related trials from the AstraZeneca program) showed both superior weight loss versus matched-dose GLP-1 monoagonist controls and meaningful hepatic fat reduction on MRI-PDFF, which is the endpoint NASH investigators actually care about.

We think the mechanism promise here is genuine. The dual-target design isn’t just stacking two agonists; the glucagon axis contributes something mechanistically distinct to the hepatic fat story. That makes cotadutide more than a me-too in the incretin space, even with tirzepatide and retatrutide in the picture. The GIP/GLP-1 axis that tirzepatide exploits and the triple agonism retatrutide is chasing are complementary programs, not direct replacements for this specific hepatic mechanism.

What we don’t love: differentiation is real but incomplete. Retatrutide already includes glucagon co-agonism as part of a more ambitious mechanism stack, which raises the question of where cotadutide fits long-term if triple agonists clear Phase 3. The NASH indication might be the answer. Resmetirom (a THR-beta agonist) is now the first approved MASH therapy, but combination approaches pairing a metabolic backbone compound with a thyroid receptor modulator are an obvious next direction, and cotadutide is a better-characterized reference for the GLP-1/glucagon axis than most alternatives in that conversation.

As a research tool, cotadutide earns its place as the reference dual GLP-1/glucagon agonist for metabolic research programs. If you want to specifically dissect what glucagon co-agonism contributes to a GLP-1 backbone in hepatic and metabolic endpoints, this is the probe you reach for. Evidence base is Phase 2 with Phase 3 ongoing, methodology is solid, and the AstraZeneca program has been transparent with the data. Honest score: real signal, useful probe, genuine mechanism differentiation, but not yet at the top tier of this class until Phase 3 reads out.

Novelty

62

Mechanism promise

76

In-category differentiation

55

Evidence quality

57

Translational signal

63

Research bench value

63

Rationale Scores well on mechanism (dual hepatic-targeted design is mechanistically distinct from pure GLP-1 agonism) and translational signal (Phase 2 data shows HbA1c, weight, and hepatic fat reduction vs matched GLP-1 controls), but differentiation is moderated by retatrutide’s triple agonism and the Phase 3 readout is still pending. Placed novel-promising given the NASH-specific research angle and genuine bench utility as the reference GLP-1/glucagon dual agonist probe.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GLP-1 / glucagon dual receptor agonist

A dual GLP-1 and glucagon receptor agonist; investigated for type 2 diabetes, NASH, and obesity.

Abstract

Cotadutide (MEDI0382; CAS 2125247-22-1; modified peptide with glucagon backbone and GLP-1 modifications; approximately 30 amino acid peptide with C16 fatty acid extension; molecular weight approximately 4140 Da) is a dual GLP-1/glucagon receptor agonist developed at AstraZeneca for type 2 diabetes, non-alcoholic steatohepatitis (NASH), and obesity. The compound is a balanced co-agonist (approximately 5:1 GLP-1:glucagon ratio at receptor). The GLP-1 component drives glucose-dependent insulin secretion, glucagon suppression, and appetite reduction; the glucagon component independently increases hepatic fatty acid oxidation, energy expenditure, and lipolysis. Phase 2 trials demonstrated superior weight loss and HbA1c reduction compared to GLP-1 monoagonists at matched dose, with hepatic fat reduction supporting the NASH indication. Plasma half-life supports once-daily subcutaneous dosing; phase 3 development is ongoing. Used as a reference dual GLP-1/glucagon agonist in metabolic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-295Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
PF-04457845

Plain-language summaryIntrigue 64 / 100

PF-04457845 is the most thoroughly studied FAAH inhibitor in humans, developed by Pfizer to raise endogenous anandamide as a non-cannabinoid approach to pain and anxiety. Phase 1 and 2 trials in osteoarthritis and fibromyalgia produced disappointing efficacy, and the compound is best remembered for its association with the 2016 Bial trial disaster in France, where a different FAAH inhibitor (BIA 10-2474) caused one death and severe neurological injury in five healthy volunteers. Subsequent investigation found the Bial compound had broad off-target lipase activity that PF-04457845 lacks, and the FAAH approach itself was not implicated. PF-04457845 is now being studied for cannabis use disorder. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

54/100

The canonical clinical-stage FAAH inhibitor, strong probe value but modest clinical payoff so far

Look, if you’re working anywhere near the endocannabinoid system, PF-04457845 is the compound you reach for. Not because it’s the flashiest thing in the library, but because it’s the cleanest, most human-validated FAAH inhibitor we have. Pfizer’s covalent piperidine-urea scaffold gives you irreversible, highly selective FAAH inhibition with a ~14-hour plasma half-life, verified target engagement in humans, and a pharmacokinetic profile that actually translates from preclinical models. Thats a short list of compounds that can claim all three.

The mechanism is worth thinking through carefully. FAAH inhibition doesn’t force receptor agonism the way a direct CB1 agonist does. Instead, it elevates the endogenous pool of N-acylethanolamides: anandamide hitting CB1/CB2 and TRPV1, OEA and PEA acting primarily through PPARs and GPR119. You get a diffuse, physiological-range modulation of multiple pathways from a single enzyme knockout. On paper, that’s elegant. The CNS penetration is real, the peripheral bioavailability is solid, and the selectivity over other serine hydrolases is among the best documented in the class.

Here’s the thing though: the clinical results have been disappointing in the indications where FAAH inhibition seemed most obvious. The 2012 Huggins et al. phase 2 in osteoarthritis pain showed clear target engagement and almost no signal on the primary endpoint. Fibromyalgia data fared similarly. What we don’t know is whether that reflects the mechanism, the compound, the indication selection, or something about how endocannabinoid tone works in chronic pain states versus acute models. That ambiguity is scientifically interesting even if its commercially discouraging.

The shadow of the 2016 Bial tragedy is worth addressing directly. BIA-10-2474, the FAAH inhibitor that killed one volunteer and injured five others in Rennes, was a different compound with different off-target liabilities. Post-incident analysis placed the blame on BIA-10-2474’s promiscuous serine hydrolase inhibition profile, not the FAAH inhibition mechanism itself. PF-04457845’s selectivity data held up under scrutiny. The tragedy did, however, cast a long institutional shadow over the class and almost certainly slowed clinical development timelines industry-wide.

Where we think PF-04457845 earns its place in a research library is as a translational probe. The recent cannabis use disorder work is genuinely more interesting than the pain programs, and the rationale for FAAH inhibition in addiction biology is mechanistically distinct enough to be worth watching. For investigators studying the ECS, comparing FAAH inhibitor selectivity profiles, or benchmarking against other endocannabinoid-elevating strategies, this is the reference compound. Its not a frontier molecule, and the bench scientist who wants the next big thing will find more novelty elsewhere. But if you’re asking whether FAAH inhibition does what you think it does in a human being, PF-04457845 is how you find out.

Novelty

42

Mechanism promise

52

In-category differentiation

62

Evidence quality

57

Translational signal

45

Research bench value

70

Rationale PF-04457845 sits at a curious intersection: it’s the most thoroughly human-characterized compound in its class and a genuine reference probe for FAAH biology, but the class has persistently underdelivered on pain efficacy and the translational signal outside cannabis use disorder remains soft. Differentiation within FAAH inhibitors is high; differentiation against the broader pain/ECS research landscape is less convincing.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective FAAH inhibitor (clinical-stage)

A clinical-stage FAAH inhibitor; the most thoroughly studied FAAH inhibitor in human trials, including a tragic phase 1 fatality at Bial.

Abstract

PF-04457845 (CAS 1020315-31-4; molecular formula C20H21F3N4O3; molecular weight 422.40) is a covalent piperidine-urea FAAH inhibitor developed at Pfizer. The compound is selective for FAAH over other serine hydrolases and produces elevated plasma and brain N-acylethanolamides (anandamide, OEA, PEA) at clinical doses. Phase 1 and 2 clinical trials in osteoarthritis pain, fibromyalgia, and (more recently) cannabis use disorder have demonstrated FAAH target engagement and modest clinical effects in some indications. The compound is most associated with the broader FAAH inhibitor scrutiny following the 2016 Bial Pharmaceuticals tragedy in Rennes, where a different FAAH inhibitor (BIA-10-2474) caused one death and severe neurological injury in a phase 1 trial; the cause was attributed to off-target effects unique to BIA-10-2474, exonerating PF-04457845 specifically. Plasma half-life is approximately 14 hours. Used as the canonical clinical-stage FAAH inhibitor for translational research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-329Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Etomidate

Plain-language summaryIntrigue 54 / 100

Etomidate is an intravenous induction anesthetic used when cardiovascular stability matters most, such as in trauma patients with low blood pressure or those with significant heart disease. It enhances GABA-A signaling at a different site than propofol and produces minimal blood pressure or heart rate changes. The major liability is adrenocortical suppression: etomidate inhibits the 11-beta-hydroxylase enzyme that synthesizes cortisol, and even a single induction dose meaningfully suppresses cortisol production for up to 24 hours. This has limited its use in septic patients, where adrenal suppression is harmful. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

48/100

Mature IV anesthetic; cardiovascular-stable reference probe with CYP11B1 inhibition as its most interesting research legacy

Look, etomidate is one of those compounds that earns its place in a research library on the strength of what it does, not how exciting it is to talk about. Approved by the FDA as Amidate back in 1972, this imidazole IV anesthetic has been a clinical fixture for over five decades, and the research community has had ample time to pick it apart. Thats actually the problem from a research-novelty standpoint: there’s not much left to discover about the parent compound.

The mechanism is worth understanding even if it isnt surprising. Etomidate acts as a positive allosteric modulator at GABA-A receptors with preferential binding to the beta-2 and beta-3 subunits. That subunit selectivity differentiates it from benzodiazepines, which prefer alpha subunit interfaces, and it’s genuinely useful as a pharmacological probe for dissecting GABA-A subtype contributions to sedation and anesthesia. Work from the Forman group at MGH and others has used etomidate-based analogues to map out the transmembrane binding pocket in real detail. As a molecular tool for that specific question, it holds up.

The more compelling research angle, honestly, is the adrenocortical suppression. Etomidate inhibits CYP11B1 (11-beta-hydroxylase), the terminal enzyme in cortisol biosynthesis, with enough potency that a single induction dose suppresses cortisol output for four to six hours. In critically ill ICU patients, this became a serious clinical concern after the Ledingham and Watt findings in the early 1980s, which drove entire analog programs: methoxycarbonyl etomidate, cyclopropyl-MOC-etomidate, and the carboetomidate series are all direct descendants of that liability. Etomidate itself is now the benchmark comparator for studying selective CYP11B1 inhibition, which carries its own therapeutic interest for adrenal excess conditions like Cushing’s syndrome.

What we like: the cardiovascular stability is real and multiply confirmed across decades of clinical use, the beta-subunit-selective GABA-A story has genuine probe value for receptor biology programs, and the CYP11B1 inhibition it revealed spawned research that is arguably more interesting than the compound itself. What we dont like: the parent compound is entirely mature. There is no frontier angle remaining on etomidate proper, and the adrenocortical liability has pushed serious investigators toward next-generation analogs rather than back to the original scaffold.

If your program involves GABA-A subunit pharmacology, CYP11B1 inhibitor screening, or steroidogenesis inhibition analog design, etomidate is a solid reference standard and a logical starting point for comparative work. As a primary research target in 2026, it’s not where you’d put your time. The interesting work is happening in what etomidate spawned, not in the original compound itself.

Novelty

22

Mechanism promise

33

In-category differentiation

48

Evidence quality

72

Translational signal

75

Research bench value

58

Rationale Approved 1972 with a thoroughly characterized mechanism, etomidate scores on evidence and translational signal but loses heavily on novelty and mechanism freshness; its primary research value today is as a reference tool for GABA-A subunit pharmacology and CYP11B1 inhibitor development, not as a primary investigation target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA-A receptor positive allosteric modulator (intravenous anesthetic)

An imidazole intravenous induction anesthetic; cardiovascular stable but causes adrenocortical suppression.

Abstract

Etomidate ((R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; CAS 33125-97-2; molecular formula C14H16N2O2; molecular weight 244.29) is an imidazole intravenous induction anesthetic developed at Janssen and approved by the FDA in 1972 (Amidate). The compound is a GABA-A receptor positive allosteric modulator with a binding site at the beta-2 and beta-3 subunits that produces preferential activity at extrasynaptic and synaptic GABA-A receptors. Distinct among IV anesthetics by minimal cardiovascular effects (preserved blood pressure and heart rate), making it preferred for patients with hemodynamic instability. The principal limitation is dose-dependent inhibition of 11-beta-hydroxylase (CYP11B1), the final enzyme in cortisol biosynthesis; even a single induction dose suppresses cortisol for 4 to 6 hours, with potential clinical consequence in critically ill patients. Plasma half-life is approximately 2 to 5 hours. Used as a reference IV anesthetic with cardiovascular stability and adrenocortical suppression.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-345Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Landogrozumab

Plain-language summaryIntrigue 48 / 100

Landogrozumab (LY2495655) is Eli Lilly’s anti-myostatin antibody, built as an IgG4 isotype to reduce immune effector function compared to the IgG1 antibodies in the class. Phase 2 trials targeted cancer cachexia, hip-fracture-associated muscle wasting, and elective total hip arthroplasty recovery, all populations where preserving lean mass might affect functional outcomes. The trials produced muscle mass increases but limited functional benefit, echoing the pattern seen across the entire myostatin-blocking class. The program was discontinued. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

40/100

Phase 2-stalled anti-myostatin mAb with real mass signal but inconsistent functional translation

Look, the anti-myostatin story is old enough to have a college degree. McPherron’s 1997 knockout mice, the early Wyeth antibody programs, Pfizer’s domagrozumab stumbling in Duchenne — the field has been trying to turn myostatin inhibition into a clinical win for a long time, and the wins keep coming out smaller than hoped. Landogrozumab doesn’t escape that pattern.

What Lilly did right is the isotype choice. IgG4 instead of IgG1 means substantially less Fc receptor engagement and complement activation, which matters a lot when you’re talking about chronic dosing in a frail or immunocompromised population. That’s not just a packaging detail; it reduces one of the real confounds in interpreting antibody studies. For any investigator who wants to neutralize myostatin cleanly without layering in Fc-mediated biology, that IgG4 format is genuinely useful.

The phase 2 data tells a complicated story. Trials in cancer cachexia, hip-fracture-associated sarcopenia, and statin-associated myopathy all showed real muscle mass increases — roughly 4 percent at six months, which is statistically detectable and mechanistically consistent. The problem is functional outcomes. Grip strength, walking speed, functional independence scores… inconsistent across the board. This is, honestly, the central unresolved question of the entire myostatin inhibition class. You can grow the muscle, but does that muscle do anything? The answer so far is: sometimes, not reliably. Development never advanced to phase 3, which tells you what Lilly concluded.

We think the comparison to bimagrumab is important context here. Bimagrumab targets ActRIIB directly, capturing not just myostatin but activin A and other ligands — that broader inhibition profile seems to produce more meaningful functional signals in some populations, particularly when combined with caloric restriction. Landogrozumab’s narrower myostatin-specific approach means cleaner mechanistic attribution in a research setting, but it also means you’re probably leaving efficacy on the table if the goal is actual functional improvement.

For bench use, the compound has a real niche. Investigators studying myostatin signaling, cachexia biology, or muscle fiber hypertrophy mechanisms have a validated, well-characterized tool here. The reduced effector function matters for clean readouts. Thats not nothing. But the clinical development story is a ceiling, not a floor, and anyone building a research program around this class needs to account for the mass-without-function problem thats defined every anti-myostatin program so far.

Novelty

32

Mechanism promise

42

In-category differentiation

30

Evidence quality

52

Translational signal

38

Research bench value

58

Rationale Scored down on novelty and differentiation because the anti-myostatin antibody class is 20+ years old and functionally outcompeted by ActRII-targeting approaches like bimagrumab; bench value is the relative bright spot because the IgG4 isotype makes it a clean myostatin probe with reduced Fc confounding for muscle biology studies. Evidence quality reflects real Lilly-backed phase 2 trials across three indications, but the mass-without-function pattern and halted development cap translational enthusiasm.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Anti-myostatin monoclonal antibody

A humanized anti-myostatin monoclonal antibody developed at Eli Lilly; investigated for cancer cachexia and muscle wasting.

Abstract

Landogrozumab (LY2495655; humanized IgG4 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized anti-myostatin monoclonal antibody developed at Eli Lilly. The IgG4 isotype reduces effector function (Fc receptor engagement, complement activation) compared to IgG1, theoretically reducing immunogenicity for chronic dosing. Phase 2 trials in cancer cachexia, hip-fracture-associated muscle loss, and statin-associated muscle pain demonstrated muscle mass increases of approximately 4 percent at 6 months but inconsistent functional improvement. Development has not advanced to phase 3. Used as a research compound for selective myostatin neutralization with reduced effector function.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-362Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lisdexamfetamine

Plain-language summaryIntrigue 70 / 100

Lisdexamfetamine is a clever prodrug of d-amphetamine, sold as Vyvanse since 2007. The trick is that the amphetamine molecule is chemically tied to the amino acid lysine, which makes the conjugate biologically inactive. Once swallowed, enzymes inside red blood cells slowly cleave the lysine off, releasing free d-amphetamine over several hours. The result is a smoother, flatter blood curve than immediate-release amphetamine and a lower abuse ceiling, since crushing or injecting it does not speed up the enzymatic conversion. Approved for ADHD and binge eating disorder. Schedule II despite the abuse-deterrent design. The standard reference for prodrug-style stimulant engineering. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

48/100

Clever abuse-deterrent prodrug chemistry that has aged into a mature, well-documented reference standard

Look, lisdexamfetamine is a genuinely clever piece of prodrug chemistry, and thats worth acknowledging upfront. The lysine conjugation approach solved a real problem in 2007: how do you deliver d-amphetamine with flat pharmacokinetics and substantially reduced abuse liability? The answer was to conjugate the active amine to L-lysine and rely on red blood cell cytosolic peptidase activity for slow, sustained cleavage. The consequence is that parenteral routes lose their pharmacokinetic advantage entirely, since the enzymatic step still has to happen. For a formulation innovation, that mechanism is elegant in a way most reformulation work isnt.

But here’s the thing: that story is nearly twenty years old now. Vyvanse launched in 2007, the prodrug chemistry was characterized and published quickly, and the field has spent the time since validating what investigators already knew. The evidence base is obviously solid. Multiple phase 3 trials across ADHD and binge eating disorder, regulatory approval in over a dozen jurisdictions, long-term safety data. We’re not disputing that lisdexamfetamine works or that the pharmacokinetic profile compares favorably to immediate-release mixed amphetamine salts in certain contexts.

What we don’t see is a research frontier. The mechanism is mature. Clinical pharmacology is fully characterized. If you’re studying dopamine transporter pharmacology at the bench, you’re using d-amphetamine itself as the tool compound, not the prodrug. If the project is specifically about prodrug cleavage kinetics or RBC enzymatic activity, that’s a narrow niche. The abuse-deterrent prodrug literature that lisdexamfetamine helped seed has been written, largely. The canonical papers are out there and the field has moved on to other problems.

We think the most credible ongoing research angle is lisdexamfetamine as a reference compound in pharmacokinetic modeling or abuse-potential comparison paradigms, and there’s some continuing interest in the BED indication where the mechanistic framing around impulse control circuitry and dopamine is at least somewhat distinct from classic ADHD pharmacotherapy. The BED evidence base is still thinner than the ADHD data, and some groups are probing executive function and emotional dysregulation endpoints in that population. That’s interesting at the margins.

Honestly, the bench value here is limited unless the program is specifically about Schedule II stimulant comparison, dopaminergic pharmacokinetics, or prodrug delivery mechanisms. The Schedule II designation adds real regulatory overhead, and the scientific upside doesn’t clear the bar to make allocation a priority. Strong evidence and translational signal from an approved drug pull the score up meaningfully; near-zero novelty and modest mechanism interest bring it back toward the middle. A serious investigator would treat this as a reference standard, not a frontier target.

Novelty

25

Mechanism promise

32

In-category differentiation

52

Evidence quality

76

Translational signal

72

Research bench value

40

Rationale Schedule II cap (65) does not bind; raw score of 48 reflects a well-evidenced approved drug with strong translational signal but near-zero frontier novelty and limited bench probe value. The lysine-conjugation prodrug story is intellectually elegant but two decades settled, pulling novelty and mechanism scores into the lower range and keeping the overall well below the schedule cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Prodrug d-amphetamine (lysine conjugate)

L-lysine-d-amphetamine conjugate; a prodrug providing slow conversion to active d-amphetamine, with reduced abuse potential.

Abstract

Lisdexamfetamine ((2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide; CAS 608137-32-2; molecular formula C15H25N3O; molecular weight 263.38) is a prodrug of d-amphetamine in which the amphetamine amino group is conjugated with L-lysine via a peptide bond. Approved by the FDA in 2007 (Vyvanse). Mechanism: the prodrug is biologically inactive; following oral absorption, red blood cell cytosolic enzymes hydrolyze the lysine-amphetamine bond, releasing free d-amphetamine over several hours. The slow, sustained release produces a flatter plasma curve than IR amphetamine and reduces the rate of dopamine increase that drives abuse liability. The lysine conjugation also means parenteral routes (IV, snorted) do not produce a faster onset, since the cleavage requires enzymatic activity. Approved indications: ADHD and binge eating disorder. Plasma half-life of the released d-amphetamine is approximately 11 hours. Schedule II. Used as the canonical abuse-deterrent stimulant prodrug.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-379Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 41 42 43 44 45 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.